TELO Q1 2025 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

TELOTelomir Pharmaceuticals, Inc. Common Stock

$46M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$2M

Net Income

-$2M

EPS (Diluted)

$-0.07

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$863,132

Free Cash Flow

-$863,132

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$491,188

Total Liabilities

$652,294

Stockholders' Equity

-$161,106

Cash & Equivalents

$402,999

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$2M	-$2M	-14.2%
Net Income	-$2M	-$6M	+65.1%